Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in liver and bile duct cancer
- Trial result
Liver and bile duct cancer
Rilvegostomig (PD-1/TIGIT bispecific) + gemcitabine/cisplatin lifts mPFS to 8.3 months in front-line biliary tract cancer
Rilvegostomig, an IgG1 bispecific antibody simultaneously blocking PD-1 and TIGIT, was combined with standard gemcitabine 1000 mg/m² + cisplatin 25 mg/m² (Days 1, 8 Q3W) in the Phase 2 GEMINI-Hepatobiliary substudy 2…
NCT05775159 - New trial
Liver and bile duct cancer
Phase 1 RPCAR01 CAR T Cells Targeting GPC3 in Advanced Hepatocellular Carcinoma
This phase 1 trial evaluates RPCAR01 CAR T cell monotherapy combined with lymphodepleting chemotherapy in patients with advanced or metastatic GPC3-positive hepatocellular carcinoma. The first-in-human study uses…
NCT06968195 - Trial result
Liver and bile duct cancer
Durvalumab + GemCis boosts 3-year survival in advanced biliary tract cancer (HR 0.74)
In the Phase III TOPAZ-1 study of patients with advanced biliary tract cancer, a combination of durvalumab and gem/cis resulted in a median OS of 12.9 months, compared to 11.3 months for the placebo with gem/cis,…
- Trial result
Liver and bile duct cancer
Durvalumab Plus GemCis Delivers Sustained Survival Benefit in Advanced
The 3-year update from the phase III TOPAZ-1 trial shows that durvalumab combined with gemcitabine and cisplatin (GemCis) significantly improved overall survival in advanced biliary tract cancer compared to…
- New trial
Liver and bile duct cancer
Phase II Study of Atezolizumab, Bevacizumab and Memantine in Hepatocellular Carcinoma
Inova is evaluating a triplet regimen—adding memantine to the standard atezolizumab and bevacizumab therapy—in locally advanced/unresectable hepatocellular carcinoma patients over 21-day cycles for six months.
NCT06789757 - New trial
Liver and bile duct cancer
A Pilot Study of 68Ga-PSMA-11 PET-directed Radioligand Therapy in Patients with Metastatic Hepatocellular Carcinoma (HCC)
This pilot study is evaluating the safety and efficacy of 177Lu-PSMA-617 radioligand therapy in PSMA-positive metastatic or unresectable HCC patients who have progressed on second-line treatments, including prior…
NCT06852820 - New trial
Liver and bile duct cancer
Regorafenib and Yttrium-90 Radioembolization for Unresectable HCC
A trial is underway at Miami to assess the impact of combining Regorafenib with Y-90 trans-arterial radioembolization in patients with unresectable hepatocellular carcinoma over an estimated 37-month period.
NCT06902246 - Trial result
Liver and bile duct cancer
Nivolumab Plus Ipilimumab as First-Line Therapy Improves Survival in Unresectable Hepatocellular Carcinoma
In the CheckMate 9DW phase 3 trial involving 668 patients with unresectable HCC, nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg), followed by nivolumab maintenance, significantly improved overall survival (median OS…
- New trial
Liver and bile duct cancer
Phase III Study: Rilvegostomig Combinations in First-line Advanced HCC
AstraZeneca is evaluating whether rilvegostomig combined with bevacizumab—with or without tremelimumab—can improve outcomes compared to atezolizumab plus bevacizumab in patients with unresectable advanced…
NCT06921785 - New trial
Liver and bile duct cancer
Phase 1b/2 Study: Ivosidenib, Durvalumab, & Gemcitabine/Cisplatin in IDH1-Mutant Cholangiocarcinoma
Institut de Recherches Internationales Servier is evaluating the safety, tolerability, and preliminary clinical activity of a combination therapy—ivosidenib with durvalumab and gemcitabine/cisplatin—as first-line…
NCT06501625 - Trial result
Liver and bile duct cancer
Tegavivint Targets β-Catenin in aHCC with Promising Safety and Activity
In this Phase 1/2 study, weekly intravenous tegavivint—a TBL1 inhibitor disrupting Wnt/β-catenin signaling—demonstrated manageable safety across dose levels (3–5 mg/kg) with some Grade 3 bilirubin elevations…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.